The U.S. Food and Drug Administration approved Lundbeck's antidepressant Brintellix to treat adults with major depressive disorder. The drug, which Lundbeck will co–market with Japanese partner Takeda Pharmaceutical Co Ltd, will be available in four doses. Brintellix, like other antidepressants, will carry a boxed warning alerting patients and doctors to an increased risk of suicidal thoughts and behavior in children, adolescents and young adults aged 18–24 during initial treatment. The most common side effects reported by patients taking the drug — generically known as vortioxetine — include nausea, constipation and vomiting.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.